Freenome
Freenome, Siemens Healthineers Partner to ID Blood-Based Breast Cancer Biomarkers
The companies aim to use multiomic and other types of data to identify blood-based biomarkers that can help in the early diagnosis of breast cancer.
Freenome Maintains CRC Early Detection Timeline as New Biomarker Discovery Studies Progress
The company is using newly raised funds to support a disseminated trial model, which it said will help it keep its plans to finish the study by the end of 2021.
Freenome Closes $270M Series C Financing to Support Early Cancer Detection Trial
The company said proceeds will accelerate the ongoing FDA registrational study of its blood-based colorectal cancer screening test and further its extended pipeline.
Freenome Begins Prospective Study of Noninvasive Colorectal Cancer Screening Test
The company enters a race to the clinic with several direct competitors, including Guardant Health and CellMax Life, as well as other firms pursuing multi-cancer screening.
The company presented new data on the performance of a multi-pronged liquid biopsy assay in detecting colorectal cancers across a range of clinical stages.